New Data From SonarMD Finds that Anxiety Increases Risks for Inflammatory Bowel Disease Flares and Disease Severity

Study Highlights the Need for Integrated Mental Health Tools in Value-Based GI Care at the Advances in Inflammatory Bowel Diseases Conference

SonarMD today presented new clinical findings describing the association between anxiety and increased risk for flares and higher disease severity in inflammatory bowel disease (IBD), emphasizing the importance of integrating mental health support within VBC models for IBD management. This poster was shared at the Advances in Inflammatory Bowel Diseases (AIBD) conference in Orlando, FL (Dec. 9-11, 2024).

The study analyzed data from patients enrolled in SonarMD’s care coordination platform, which integrates proactive patient engagement, disease activity monitoring, and risk stratification, acting as an extension of the gastroenterology practice. The results underscore the heightened burden of anxiety and its clinical implications.

Study Highlights:

  • Prevalence of Anxiety Symptoms: Among 643 IBD patients, 11.8% screened positive for symptoms of anxiety (GAD-2 score ≥3).
  • Comorbid Depression: Anxiety symptoms were associated with a fivefold increase in depressive symptoms, with 49% of symptomatically anxious patients also meeting criteria for depression (PHQ-2 score ≥3).
  • Disease Severity: Patients with anxiety symptoms were significantly more likely to have high disease severity at baseline, with 42% categorized in the top quintile of disease risk compared to 15% of non-anxious symptom patients.
  • Increased Risk of Flares: Over a six-month follow-up, patients with anxiety exhibited a nearly doubled flare rate (25%) compared to non-anxious counterparts (13%).

“These findings demonstrate that mental health factors like anxiety play a critical role in the clinical course of IBD,” said Beth Houck, CEO, SonarMD “By identifying and addressing psychological contributors, we can refine value-based care models to better support patients with chronic digestive diseases. Integrated care models that incorporate mental health screening and interventions should be considered a standard for high-quality IBD care.”

The data reinforces the importance of a multidisciplinary approach to IBD management within VBC frameworks, where mental health support complements physical health monitoring. SonarMD has a scalable VBC model in place that seamlessly incorporates mental health tools to support comprehensive patient care and improve patient outcomes.

SonarMD will present this data today, December 11th at the AIBD conference, held at the Walt Disney World Swan & Dolphin Resort in Orlando, Florida.

 

SourceSonarMD

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version